
Clean Science Q1 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- HALS segment volume target: Aspirational ramp-up to 150-200 tons per month in coming months; aiming for ~2,000 tons sales volume in FY'25 and 2,500-3,000 tons by FY'26 (50% capacity utilization).
- Revenue from new HALS capacity aimed at $7-$8/kg realization.
- Performance Chemicals segment and other products like MEHQ, DCC, TBHQ showing growing volumes and utilization around 65-70%.
- Volume growth is the primary driver for revenue increase; price realizations remain stable or slightly lower.
- Plans for INR 300 crore capex in FY'25 to expand capacities mainly in Performance Chemicals and Pharma intermediates, expected to enhance future sales.
- Targeting 70-75% of the Indian HALS market with expansion into Asian, American, and European export markets.
- Sustained quarter-on-quarter volume growth expected, with ongoing ramp-up of commercial production and new product launches supporting revenue growth.
See what Clean Science management said on margin guidance — free account, 30 seconds.
Fundraise plans
- There is no explicit mention of any current or planned fundraising through debt or equity in the transcript.
- The company has invested significantly in subsidiaries and capex, including INR150 crores for a new performance chemicals plant and INR30 crores for pharma intermediates.
- Investments in the subsidiary (CFCL) have been funded by the parent company, with a total infusion of INR435 crores as of now.
- No indication from management about raising external funds through equity or debt during this period.
- Focus appears to be on internal funding and organic growth through capex and product commercialization.
See what Clean Science management said on order book — free account, 30 seconds.
Capex plans
Yes- Q1 FY'25 capex of ~INR100 crores primarily invested in subsidiary Clean Fino-Chem Limited (CFCL).
- Pharma intermediates plant: INR30 crores capex, expected commercialization by Q3 FY'25.
- Performance Chemicals segment:
- - INR150 crores capex plant under construction at subsidiary, targeting commercialization by H1 FY'26, expected to address 15% of global market demand.
- - Another INR150 crores capex starting September 2024, focusing on water treatment chemicals, with 10-12 months construction and water trials timeline.
- Total planned capex around INR300 crores across these projects, with some spillover into FY'26.
- Future capex decisions for legacy products and capacity expansion to be evaluated by end of 2024 based on market absorption.
- Additional investment planned in 6 MW solar plant to improve ESG and reduce power costs.
Track Clean Science — get its next earnings analysis in your feed
How does Clean Science rank vs peers in Chemicals & Petrochemicals?
Pro featureHow does Clean Science rank in Chemicals & Petrochemicals?
Compare Clean Science against every Chemicals & Petrochemicals company (Q1 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Clean Science's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Seya Industries (Q2 FY27)
Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's
- DCM Shriram Fine Chemicals (Q2 FY27)
9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri
- Dhariwalcorp (Q2 FY27)
For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…
- Agastya Energy (Q2 FY27)
For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…